ORTX Stock Overview
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.05|
|52 Week High||US$9.08|
|52 Week Low||US$1.04|
|1 Month Change||-16.00%|
|3 Month Change||-48.53%|
|1 Year Change||-83.85%|
|3 Year Change||-91.43%|
|5 Year Change||n/a|
|Change since IPO||-92.50%|
Recent News & Updates
|ORTX||US Biotechs||US Market|
Return vs Industry: ORTX underperformed the US Biotechs industry which returned -18.4% over the past year.
Return vs Market: ORTX underperformed the US Market which returned 10.2% over the past year.
|ORTX Average Weekly Movement||10.6%|
|Biotechs Industry Average Movement||10.2%|
|Market Average Movement||6.6%|
|10% most volatile stocks in US Market||15.7%|
|10% least volatile stocks in US Market||2.4%|
Stable Share Price: ORTX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: ORTX's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company’s gene therapy approach seeks to transform a patient’s hematopoietic stem cells into a gene-modified cellular drug product to treat the patient’s disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID).
Orchard Therapeutics Fundamentals Summary
|ORTX fundamental statistics|
Is ORTX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ORTX income statement (TTM)|
|Cost of Revenue||-US$476.00k|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-1.13|
|Net Profit Margin||-11,900.67%|
How did ORTX perform over the long term?See historical performance and comparison
Is Orchard Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ORTX's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ORTX's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ORTX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: ORTX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ORTX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ORTX is good value based on its PB Ratio (0.5x) compared to the US Biotechs industry average (2.1x).
How is Orchard Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ORTX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ORTX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ORTX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ORTX's revenue (60.4% per year) is forecast to grow faster than the US market (9.2% per year).
High Growth Revenue: ORTX's revenue (60.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ORTX is forecast to be unprofitable in 3 years.
How has Orchard Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ORTX is currently unprofitable.
Growing Profit Margin: ORTX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ORTX is unprofitable, and losses have increased over the past 5 years at a rate of 10.4% per year.
Accelerating Growth: Unable to compare ORTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ORTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).
Return on Equity
High ROE: ORTX has a negative Return on Equity (-58.79%), as it is currently unprofitable.
How is Orchard Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: ORTX's short term assets ($291.5M) exceed its short term liabilities ($44.2M).
Long Term Liabilities: ORTX's short term assets ($291.5M) exceed its long term liabilities ($70.1M).
Debt to Equity History and Analysis
Debt Level: ORTX has more cash than its total debt.
Reducing Debt: Insufficient data to determine if ORTX's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ORTX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ORTX has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 24% each year.
What is Orchard Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ORTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ORTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ORTX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ORTX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ORTX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Bobby Gaspar (56 yo)
Dr. Bobby Gaspar, M.D., Ph.D. has been Chief Executive Officer at Orchard Therapeutics plc (Formerly known as Orchard Therapeutics Limited) since March 18, 2020. He serves as a Director at Alliance for Reg...
CEO Compensation Analysis
Compensation vs Market: Bobby's total compensation ($USD3.78M) is above average for companies of similar size in the US market ($USD579.29K).
Compensation vs Earnings: Bobby's compensation has increased whilst the company is unprofitable.
Experienced Management: ORTX's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Experienced Board: ORTX's board of directors are considered experienced (3.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 28.4%.
Orchard Therapeutics plc's employee growth, exchange listings and data sources
- Name: Orchard Therapeutics plc
- Ticker: ORTX
- Exchange: NasdaqGS
- Founded: 2015
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$131.774m
- Shares outstanding: 125.50m
- Website: https://www.orchard-tx.com
Number of Employees
- Orchard Therapeutics plc
- 108 Cannon Street
- Greater London
- EC4N 6EU
- United Kingdom
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/19 23:50|
|End of Day Share Price||2022/01/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.